“Cost-Effectiveness Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes and Established Cardiovascular Disease in Italy, Based on the Results of the EMPA-REG OUTCOME Study”. Farmeconomia. Health Economics and Therapeutic Pathways, vol. 18, no. 1, Oct. 2017, https://doi.org/10.7175/fe.v18i1.1332.